Development

A single infusion permanently lowers cholesterol

development2026-05-25

Claim

Verve Therapeutics showed VERVE-102 produces dose-dependent, substantial and sustained reductions in PCSK9 and LDL cholesterol from a single Phase 1 infusion, effectively a permanent one-shot gene therapy for cardiovascular risk.

Reporting date: 2026-05-25 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to May 25, 2026 (theinnermostloop.substack.com)

Knowledge graphopen in browser →

Reported in

Welcome to May 25, 2026

Actor

Evidence for

Biology engineered past the constraints of life

Supersedes

A one-time CAR-T therapy controls HIV in a first-in-human trial

Referenced by

Welcome to May 25, 2026

Cite or correct this record

Citation formatCitation text

A single infusion permanently lowers cholesterol
Innermost Loop KB — secondary record
Reporting date: 2026-05-25
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-05-25-a-single-infusion-lowers-cholesterol-permanently
Claim: Verve Therapeutics showed VERVE-102 produces dose-dependent, substantial and sustained reductions in PCSK9 and LDL cholesterol from a single Phase 1 infusion, effectively a permanent one-shot gene therapy for cardiovascular risk.
Attributed sources:
- Welcome to May 25, 2026 — https://theinnermostloop.substack.com/p/welcome-to-may-25-2026
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.